Gene-editing, Moderna, and transhumanism
From the blog of Christina Lin at The Times of Israel
blogs.timesofisrael.com
With U.S. government funding at nearly $1 billion for one company, Moderna may be too big to fail. However, this is perplexing for a company that has never produced a single vaccine. According to a
CNN report, Moderna was only established in 2010, has never brought a product to market, nor gotten any of its nine or so vaccine candidates approved for use by the FDA.
However, it has been a long-term Pentagon contractor for biodefense, working closely with Defense Advanced Research Project Agency
(DARPA) on gene-editing and mRNA therapeutics. DARPA is focused on developing emerging disruptive technologies to maintain a competitive edge over adversaries, including many ‘transhuman’ projects such as genetic engineering and
soldier enhancement via robotics.